The use of tobramycin for Pseudomonas aeruginosa: a review

References

• Gershman AJ, Mehta AC, Infeld M, et al. Cystic fibrosis in adults: an overview for the internist. Cleve Clin J Med. 2006 Dec;73(12):1065–1074.
   PubMed Web of Science ®Google Scholar
• Cystic Fibrosis Foundation. Patient registry annual data report. Accessed 2021 Jun 7. https://www.cff.org/Research/Researcher-Resources/Patient-Registry/2019-Patient-Registry-Annual-Data-Report.pdf
   Google Scholar
• Briaud P, Camus L, Bastien S, et al. Coexistence with Pseudomonas aeruginosa alters Staphylococcus aureus transcriptome, antibiotic resistance and internalization into epithelial cells. Sci Rep. 2019 Nov 12;9(1):16564.
   PubMedGoogle Scholar
• Cystic Fibrosis Foundation. Pseudomonas. Available to 2021 Apr 20. https://www.cff.org/Life-With-CF/Daily-Life/Germs-and-Staying-Healthy/What-Are-Germs/Pseudomonas/
   Google Scholar
• Jarad NA, Higgs S, Jeffcote T, et al. Factors associated with reduced FEV1 in adult patients with cystic fibrosis in a relatively affluent area. Chron Respir Dis. 2005;2(3):133–137.
   PubMedGoogle Scholar
• Lechtzin N, John M, Irizarry R, et al. Outcomes of adults with cystic fibrosis infected with antibiotic-resistant Pseudomonas aeruginosa. Respiration. 2006;73(1):27–33.
   PubMed Web of Science ®Google Scholar
• Emerson J, Rosenfeld M, McNamara S, et al. Pseudomonas aeruginosa and other predictors of mortality and morbidity in young children with cystic fibrosis. Pediatr Pulmonol. 2002 Aug;34(2):91–100.
   PubMed Web of Science ®Google Scholar
• Starner TD, McCray PB Jr. American College of P, American Physiological S. Pathogenesis of early lung disease in cystic fibrosis: a window of opportunity to eradicate bacteria. Ann Intern Med. 2005 Dec 6;143(11):816–822.
   PubMed Web of Science ®Google Scholar
• Mogayzel PJ Jr., Naureckas ET, Robinson KA, et al. Cystic fibrosis foundation pulmonary guideline. pharmacologic approaches to prevention and eradication of initial Pseudomonas aeruginosa infection. Ann Am Thorac Soc. 2014 Dec;11(10):1640–1650.
   PubMedGoogle Scholar
• Castellani C, Duff AJA, Bell SC, et al. ECFS best practice guidelines: the 2018 revision. J Cyst Fibros. 2018 Mar;17(2):153–178
   PubMed Web of Science ®Google Scholar
• Mogayzel PJ Jr., Naureckas ET, Robinson KA, et al. Cystic fibrosis pulmonary guidelines. Chronic medications for maintenance of lung health. Am J Respir Crit Care Med. 2013 Apr 1;187(7):680–689
   PubMed Web of Science ®Google Scholar
• TOBI Podhaler. Package insert. Novartis; 2016. Available to 2021 Apr 23. https://www.novartis.us/sites/www.novartis.us/files/tobipodhaler.pdf
   Google Scholar
• Podhaler TOBI. Summary of product characteristics. Available to 2021 Apr 23. https://www.ema.europa.eu/en/documents/product-information/tobi-podhaler-epar-product-information_en.pdf
   Google Scholar
• Geller DE, Konstan MW, Smith J, et al. Novel tobramycin inhalation powder in cystic fibrosis subjects: pharmacokinetics and safety. Pediatr Pulmonol. 2007 Apr;42(4):307–313.
   PubMed Web of Science ®Google Scholar
• Ting L, Aksenov S, Bhansali SG, et al. Population pharmacokinetics of inhaled tobramycin powder in cystic fibrosis patients. CPT Pharmacometrics Syst Pharmacol. 2014 Feb 12;3:e99
   PubMedGoogle Scholar
• Choi J, Novak K, Thompson R. Evaluation of inhaled tobramycin in early eradication of pseudomonas aeruginosa in infants with cystic fibrosis. J Pediatr Pharmacol Ther. 2020;25(8):709–716.
   PubMedGoogle Scholar
• Ratjen F, Moeller A, McKinney ML, et al. Eradication of early P. aeruginosa infection in children <7 years of age with cystic fibrosis: the early study. J Cyst Fibros. 2019 Jan;18(1):78–85.
   PubMed Web of Science ®Google Scholar
• Akkerman-Nijland AM, Yousofi M, Rottier BL, et al. Eradication of pseudomonas aeruginosa in cystic fibrosis patients with inhalation of dry powder tobramycin. Ther Adv Respir Dis. 2020Jan-Dec;14:1753466620905279.
   Web of Science ®Google Scholar
• Konstan MW, Geller DE, Minic P, et al. Tobramycin inhalation powder for P. aeruginosa infection in cystic fibrosis: the EVOLVE trial. Pediatr Pulmonol. 2011 Mar;46(3):230–238.
   PubMed Web of Science ®Google Scholar
• Galeva I, Konstan MW, Higgins M, et al. Tobramycin inhalation powder manufactured by improved process in cystic fibrosis: the randomized EDIT trial. Curr Med Res Opin. 2013 Aug;29(8):947–956
   PubMed Web of Science ®Google Scholar
• Konstan MW, Flume PA, Kappler M, et al. Safety, efficacy and convenience of tobramycin inhalation powder in cystic fibrosis patients: the EAGER trial. J Cyst Fibros. 2011 Jan;10(1):54–61.
   PubMed Web of Science ®Google Scholar
• Geller DE, Nasr SZ, Piggott S, et al. Tobramycin inhalation powder in cystic fibrosis patients: response by age group. Respir Care. 2014 Mar;59(3):388–398.
   PubMed Web of Science ®Google Scholar
• Konstan MW, Flume PA, Galeva I, et al. One-year safety and efficacy of tobramycin powder for inhalation in patients with cystic fibrosis. Pediatr Pulmonol. 2016 Apr;51(4):372–378.
   PubMed Web of Science ®Google Scholar
• Sommerwerck U, Virella-Lowell I, Angyalosi G, et al. Long-term safety of tobramycin inhalation powder in patients with cystic fibrosis: phase IV (ETOILES) study. Curr Med Res Opin. 2016 Nov;32(11):1789–1795.
   PubMed Web of Science ®Google Scholar
• Hamed K, Debonnett L. Tobramycin inhalation powder for the treatment of pulmonary Pseudomonas aeruginosa infection in patients with cystic fibrosis: a review based on clinical evidence. Ther Adv Respir Dis. 2017 May; 11(5):193–209.
   PubMed Web of Science ®Google Scholar
• Meerburg JJ, Albasri M, van der Wiel EC, et al. Home videos of cystic fibrosis patients using tobramycin inhalation powder: relation of flow and cough. Pediatr Pulmonol. 2019 Nov;54(11):1794–1800
   PubMed Web of Science ®Google Scholar
• Sawicki GS, Sellers DE, Robinson WM. High treatment burden in adults with cystic fibrosis: challenges to disease self-management. J Cyst Fibros. 2009 Mar;8(2):91–96.
   PubMed Web of Science ®Google Scholar
• American Association for Respiratory Care. A patient’s guide to aerosol medication delivery. 2017. Available to 2021 Jun 26. https://www.aarc.org/wp-content/uploads/2018/01/aerosol-guides-for-patients-3rd.pdf
   Google Scholar
• Saiman L, Siegel J. Infection control in cystic fibrosis. Clin Microbiol Rev. 2004 Jan;17(1):57–71
   PubMed Web of Science ®Google Scholar
• Lester MK, Flume PA, Gray SL, et al. Nebulizer use and maintenance by cystic fibrosis patients: a survey study. Respir Care. 2004 Dec;49(12):1504–1508.
   PubMedGoogle Scholar
• Blau H, Mussaffi H, Mei Zahav M, et al. Microbial contamination of nebulizers in the home treatment of cystic fibrosis. Child Care Health Dev. 2007 Jul;33(4):491–495.
   PubMed Web of Science ®Google Scholar
• Hurley MN, McKeever TM, Prayle AP, et al. Rate of improvement of CF life expectancy exceeds that of general population–observational death registration study. J Cyst Fibros. 2014 Jul;13(4):410–415.
   PubMed Web of Science ®Google Scholar
• Hamed K, Conti V, Tian H, et al. Adherence to tobramycin inhaled powder vs inhaled solution in patients with cystic fibrosis: analysis of US insurance claims data. Patient Prefer Adherence. 2017;11:831–838.
   PubMed Web of Science ®Google Scholar
• Blasi F, Carnovale V, Cimino G, et al. Treatment compliance in cystic fibrosis patients with chronic Pseudomonas aeruginosa infection treated with tobramycin inhalation powder: the FREE study. Respir Med. 2018May;138:88–94.
   PubMed Web of Science ®Google Scholar
• Lam J, Vaughan S, Parkins MD. Tobramycin inhalation powder (TIP): an efficient treatment strategy for the management of chronic pseudomonas aeruginosa infection in cystic fibrosis. Clin Med Insights Circ Respir Pulm Med. 2013 Nov 13;7:61–77
   PubMedGoogle Scholar
• Greenwood J, Schwarz C, Sommerwerck U, et al. Ease of use of tobramycin inhalation powder compared with nebulized tobramycin and colistimethate sodium: a crossover study in cystic fibrosis patients with pulmonary Pseudomonas aeruginosa infection. Ther Adv Respir Dis. 2017 Jul;11(7):249–260.
   PubMed Web of Science ®Google Scholar
• Greenberg J, Palmer JB, Chan WW, et al. Treatment satisfaction in cystic fibrosis: early patient experience with tobramycin inhalation powder. Patient Prefer Adherence. 2016;10:2163–2169.
   PubMed Web of Science ®Google Scholar
• Burns JL, Emerson J, Stapp JR, et al. Microbiology of sputum from patients at cystic fibrosis centers in the United States. Clin Infect Dis. 1998 Jul;27(1):158–163.
   PubMed Web of Science ®Google Scholar
• Geller DE, Pitlick WH, Nardella PA, et al. Pharmacokinetics and bioavailability of aerosolized tobramycin in cystic fibrosis. Chest. 2002 Jul;122(1):219–226.
   PubMed Web of Science ®Google Scholar
• Loebinger MR, Polverino E, Chalmers JD, et al. Efficacy and safety of TOBI Podhaler in Pseudomonas aeruginosa- infected bronchiectasis patients: iBEST study. Eur Respir J. 2021 Jan;57(1).
   PubMed Web of Science ®Google Scholar
• Loebinger MR, Polverino E, Blasi F, et al. Efficacy and safety of tobramycin inhalation powder in bronchiectasis patients with P. aeruginosa infection: DESIGN of a dose-finding study (iBEST-1). Pulm Pharmacol Ther. 2019Oct;58:101834.
   PubMed Web of Science ®Google Scholar
• Eyns H, Pierard D, De Wachter E, et al. Respiratory bacterial culture sampling in expectorating and non-expectorating patients with cystic fibrosis. Front Pediatr. 2018;6:403.
   PubMed Web of Science ®Google Scholar
• Volkova N, Moy K, Evans J, et al. Disease progression in patients with cystic fibrosis treated with ivacaftor: data from national US and UK registries. J Cyst Fibros. 2020 Jan;19(1):68–79.
   PubMed Web of Science ®Google Scholar
• Frost FJ, Nazareth DS, Charman SC, et al. Ivacaftor is associated with reduced lung infection by key cystic fibrosis pathogens. a cohort study using national registry data. Ann Am Thorac Soc. 2019 Nov;16(11):1375–1382.
   PubMed Web of Science ®Google Scholar